Seminars in Thrombosis and Hemostasis Seminars in Thrombosis and Hemostasis RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Evolution of Antiphospholipid Syndrome
Semin Thromb Hemost DOI: 10.1055/s-0042-1760333Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disease characterized by thrombosis and/or pregnancy complications caused by antiphospholipid antibodies (aPL). The history of APS can be traced back to observations made during screening programs for syphilis conducted in the mid-20th century, with identification of patients with the so-called biological false-positive serological reactions for syphilis. Initial observation linking aPL with recurrent miscarriages was first reported more than 40 years ago. Since then, our understanding of the pathogenesis and manag...
Source: Seminars in Thrombosis and Hemostasis - January 16, 2023 Category: Hematology Authors: Arachchillage, Deepa J. Pericleous, Charis Tags: Review Article Source Type: research

Maternal and Neonatal Hemostasis
Semin Thromb Hemost DOI: 10.1055/s-0042-1760331 Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - January 16, 2023 Category: Hematology Authors: Kenet, Gili Brenner, Benjamin Tags: Preface Source Type: research

Erratum: Septic Pulmonary Embolism. A Contemporary Profile
Semin Thromb Hemost DOI: 10.1055/s-0043-1760843 Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - January 16, 2023 Category: Hematology Authors: Valerio, Luca Baddour, Larry M. Tags: Erratum Source Type: research

Causal Associations Between Cardiovascular Risk Factors and Venous Thromboembolism
Conclusion Our study supports that BMI is a causal risk factor for VTE, DVT, and PE. SBP is a protective factor for VTE and PE. Physical activity is a protective factor for DVT. However, the effects of other cardiovascular risk factors are not identified. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - January 11, 2023 Category: Hematology Authors: Hu, Mengjin Li, Xiaosong Yang, Yuejin Tags: Review Article Source Type: research

Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Semin Thromb Hemost DOI: 10.1055/s-0042-1760330Anticoagulant therapy is the cornerstone of treatment and prevention of arterial and venous thromboembolism. Taking a historical perspective, starting in the 1960s, and progressing through to 2022, we discuss key clinical trials of anticoagulants that have changed clinical practice, and examine obstacles encountered in bringing these anticoagulants to the clinic. The design of some of the early studies that shaped clinical practice was poor by current standards, but their results were influential because nothing better was available. Both heparin and vitamin K antagonists had ...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2023 Category: Hematology Authors: Hirsh, Jack de Vries, Tim A.C. Eikelboom, John W. Bhagirath, Vinai Chan, Noel C. Tags: Review Article Source Type: research

The Future of Laboratory-Developed Tests in Hemostasis Laboratories
Semin Thromb Hemost DOI: 10.1055/s-0042-1760361Laboratory-developed tests (LDTs) are widely used in clinical hemostasis laboratories. The extent to which LDTs are regulated varies greatly around the world, and proposed changes to regulations have raised concerns about the future of LDTs in clinical laboratories. It is increasingly difficult to justify the use of an LDT where a commercially available method with regulatory approval is available. Conversely, where there is no suitable test with regulatory approval and there is a compelling clinical need, using an LDT outweighs the risk associated with not performing the test...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2023 Category: Hematology Authors: Gardiner, Chris Echenagucia, Mari ón Gosselin, Robert C. Tags: Review Article Source Type: research

COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications
Semin Thromb Hemost 2023; 49: 009-014 DOI: 10.1055/s-0042-1759684Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been reported in association with the coronavirus disease 2019 preventative adenovirus vector-based vaccines ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) in hundreds of recipients across the globe. VITT is characterized by thrombosis, typically at unusual sites, low fibrinogen, and elevated plasma D-dimer, generally manifesting between 4 and 28 days following vaccination. Detection of anti-platelet factor antibodies using an enzyme-linked immunosorbent assay ...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2023 Category: Hematology Authors: Zidan, Ali Noureldin, Abdelrahman Kumar, Shreya Anil Elsebaie, Abdelrahman Othman, Maha Tags: Review Article Source Type: research

Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19) —Part IV
Semin Thromb Hemost 2023; 49: 003-008 DOI: 10.1055/s-0042-1759736 Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - January 5, 2023 Category: Hematology Authors: Favaloro, Emmanuel J. Pasalic, Leonardo Lippi, Giuseppe Tags: Preface Source Type: research

Welcome to Seminars in Thrombosis & Hemostasis 2023
Semin Thromb Hemost 2023; 49: 001-002 DOI: 10.1055/s-0042-1759685 Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - January 5, 2023 Category: Hematology Authors: Favaloro, Emmanuel J. Tags: Editorial Source Type: research

Celebrating 50 Years of Seminars in Thrombosis and Hemostasis —Part II
Semin Thromb Hemost DOI: 10.1055/s-0042-1760334 Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - December 30, 2022 Category: Hematology Authors: Favaloro, Emmanuel J. Tags: Preface Source Type: research

Dedication: Professor Peter Kubisz (1942 –2022) – Un hommage à trois étincelles
Semin Thromb Hemost DOI: 10.1055/s-0042-1760198 Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents  |  Full text (Source: Seminars in Thrombosis and Hemostasis)
Source: Seminars in Thrombosis and Hemostasis - December 26, 2022 Category: Hematology Authors: Ruiz-Arg üelles, Guillermo J. Tags: Dedication Source Type: research

Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review
Semin Thromb Hemost DOI: 10.1055/s-0042-1759683Cancer and pregnancy induce a procoagulant environment which may lead to maternal and fetal complications, such as venous thromboembolism, fetal growth restriction, and fetal loss. The incidence of hematological malignancies diagnosed during pregnancy is rising, and thrombotic events in such malignancies are not rare. Management of thrombosis during pregnancy poses a therapeutic challenge, that is further exacerbated by the impact of cancer. The available data on managing pregnant women with hematological malignancies are limited to those with myeloproliferative neoplasms, mai...
Source: Seminars in Thrombosis and Hemostasis - December 19, 2022 Category: Hematology Authors: Krayem, Baher Brenner, Benjamin Horowitz, Netanel A. Tags: Review Article Source Type: research

Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)
Semin Thromb Hemost DOI: 10.1055/s-0042-1758791Plasminogen activator inhibitor 1 (PAI-1), a SERPIN inhibitor, is primarily known for its regulation of fibrinolysis. However, it is now known that this inhibitor functions and contributes to many (patho)physiological processes including inflammation, wound healing, cell adhesion, and tumor progression.This review discusses the past, present, and future roles of PAI-1, with a particular focus on the discovery of this inhibitor in the 1970s and subsequent characterization in health and disease. Throughout the past few decades diverse functions of this serpin have unraveled and ...
Source: Seminars in Thrombosis and Hemostasis - December 15, 2022 Category: Hematology Authors: Morrow, Gael B. Mutch, Nicola J. Tags: Review Article Source Type: research

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
Semin Thromb Hemost DOI: 10.1055/s-0042-1758870Accurate measurement of clotting factors VIII (FVIII) or IX (FIX) is vital for comprehensive diagnosis and management of patients with hemophilia A or B. The one-stage activated partial thromboplastin time (aPTT)-based clotting assay is the most commonly used method worldwide for testing FVIII or FIX activities. Alternatively, FVIII and FIX chromogenic substrate assays, which assess the activation of factor X, are available in some specialized laboratories. The choice of reagent or methodology can strongly influence the resulting activity. Variation between one-stage FVIII or ...
Source: Seminars in Thrombosis and Hemostasis - December 6, 2022 Category: Hematology Authors: Bowyer, Annette E. Gosselin, Robert C. Tags: Review Article Source Type: research

Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review
Semin Thromb Hemost DOI: 10.1055/s-0042-1758818Heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT) are highly prothrombotic (thrombosis frequency ≥50%). Both are caused by platelet-activating anti-platelet factor 4 (PF4) antibodies, forming PF4/IgG-containing immune complexes that engage platelet FcγIIa receptors, producing strong platelet activation. In HIT, heparin crosslinks several PF4 molecules, whereas in VITT, anti-PF4 antibodies alone crosslink PF4. Sufficient levels of circulating anti-PF4 antibodies are needed to create the pathogenic immune complexes on platele...
Source: Seminars in Thrombosis and Hemostasis - December 1, 2022 Category: Hematology Authors: Warkentin, Theodore E. Greinacher, Andreas Tags: Review Article Source Type: research